放射性标记抗体治疗癌症的新时代来临？

A new era for radiolabeled antibodies in cancer?

作者信息

DeNardo S J, Kroger L A, DeNardo G L

机构信息

Molecular Cancer Institute, Hematology/Oncology Department, University of California Davis Medical Center, 1508 Alhambra Boulevard, Room 3100, Sacramento, CA 95816, USA.

出版信息

Curr Opin Immunol. 1999 Oct;11(5):563-9. doi: 10.1016/s0952-7915(99)00017-5.

DOI:10.1016/s0952-7915(99)00017-5

PMID:10508716

Abstract

Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.

摘要

放射免疫疗法（RIT）是一种针对肿瘤细胞的治疗方法，是一种目前能够将辐射传递至肿瘤细胞的剂量比传递至接受次高剂量辐射的正常组织的剂量高3至50倍的治疗方式。放射免疫疗法在未来癌症治疗方面似乎很有前景。晚期癌症患者经常通过单独使用放射免疫疗法取得临床疗效。在淋巴瘤患者中已实现了延长的完全缓解甚至生存期延长。放射免疫疗法用于联合治疗时，在其他癌症中似乎也可能取得类似结果。